9
8
Chem. Res. Toxicol., Vol. 9, No. 1, 1996
Narimatsu et al.
(
6) Weissman, J ., Trevor, A., Chiba, K., Peterson, L. A., Caldera, P.,
Castagnoli, N., J r., and Baillie, T. (1985) Metabolism of the
negrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
by liver homogenate fractions. J . Med. Chem. 28, 997-1001.
7) Cashman, J . R., and Ziegler, D. M. (1986) Contribution of
N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-
(20) Omura, T., and Sato, R. (1964) The carbon monoxide-binding
pigment of liver microsomes. I. Evidence for its hemoprotein
nature. J . Biol. Chem. 239, 2370-2378.
(21) Suzuki, T., Narimatsu, S., Fujita, S., Masubuchi, Y., Umeda, S.,
Imaoka, S., and Funae, Y. (1992) Purification and characterization
of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxy-
lation in liver microsomes of male rats. Drug Metab. Dispos. 20,
367-373.
(22) Fujita, S., Morimoto, R., Chiba, M., Kitani, K., and Suzuki, T.
(1989) Evaluation of the involvement of a male specific cytochrome
P-450 isozyme in senescence-associated decline of hepatic drug
metabolism in male rats. Biochem. Pharmacol. 38, 3925-3931.
(23) Yasukochi, Y., and Masters, B. S. S. (1976) Some properties of
detergent-solubilized NADPH-cytochrome c (cytochrome P-450)
reductase purified by biospecific affinity chromatography. J . Biol.
Chem. 251, 5337-5344.
(24) Lowry, O. H., Rosebrough, N. J ., Farr, A. L., and Randall, R. J .
(1951) Protein measurement with the Folin phenol reagent. J .
Biol. Chem. 193, 265-275.
(25) Yamaoka, K., Tanigawara, Y., Nakagawa, T., and Uno, T. (1981)
A pharmacokinetic analysis program (MULTI) for microcomputer.
J . Pharmacobio-Dyn. 4, 879-885.
(26) Masubuchi, Y., Fujita, S., Chiba, M., Kagimoto, N., Umeda, S.,
and Suzuki, T. (1991) Impairment of debrisoquine 4-hydroxylase
and related monooxygenase activities in the rat following treat-
ment with propranolol. Biochem. Pharmacol. 41, 861-865.
(27) Al-Dabbagh, S. G., Idle, J . R., and Smith, R. L. (1981). Animal
modelling of human polymorphic drug oxidationsmetabolism of
debrisoquine and phenacetin in rat inbred strains. J . Pharm.
Pharmacol. 33, 161-164.
(28) Guengerich, F. P. (1987) Enzymology of rat liver cytochrome
P-450. In Mammalian Cytochromes P-450 Vol. I, (Guengerich,
F. P., Ed.) pp 1-54, CRC Press, Boca Raton, FL.
(29) J imenez-J imenez, F. J ., Tabernero, C., Mena, M. A., Yebenes, J .
G., Yebenes, M. J . G., Casarejos, M. J ., Pardo, B., Garcia-Agundez,
J . A., Benitez, J ., Martinez, A., and Garcia-Asenjo, J . A. L. (1991)
Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in
a model of rat designated a poor metabolizer of debrisoquine. J .
Neurochem. 57, 81-87.
(30) Tyndale, R. F., Sunahara, R., Inaba, T., Kalow, W., Gonzalez, F.
J ., and Niznik, H. B. (1991) Neuronal cytochrome P450IID1
(debrisoquine/sparteine-type): potent inhibition of activity by (-)-
cocaine and nucleotide sequence identity to human hepatic P450
gene CYP2D6. Mol. Pharmacol. 40, 63-68.
(31) Komori, M. (1993) A novel P450 expressed at the high level in
rat brain. Biochem. Biophys. Res. Commun. 196, 721-728.
(
1
,2,3,6-tetrahydropyridine) by various liver preparations. Mol.
Pharmacol. 29, 163-169.
(8) Chiba, K., Kubota, E., Miyakawa, T., Kato, Y., and Ishizaki, T.
(1988) Characterization of hepatic microsomal metabolism as an
in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine in mice. J . Pharmacol. Exp. Ther. 246, 1108-
1
115.
(
9) Smith, M. T., Ekstrom, G., Sandy, M. S., and Di Monte, D. (1987)
Studies on the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine cytotoxicity in isolated hepatocytes. Life Sci. 40 741-
7
48.
(
10) Ottoboni, S., Carlson, T. J ., Trager, W. F., Castagnoli, K., and
Castagnoli, N., J r. (1990) Studies on the cytochrome P-450
catalyzed ring R-carbon oxidation of the nigrostriatal toxin
1
-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chem.
Res. Toxicol. 3, 423-427.
(
(
(
11) Monte, D. D., Shinka, T., Sandy, M. S., Castagnoli, N., J r., and
Smith, M. T. (1988) Quantitative analysis of 1-methyl-4-phenyl-
1
,2,3,6-tetrahydropyridine metabolism in isolated rat hepatocytes.
Drug Metab. Dispos. 16, 250-255.
12) Lau, Y.-S., Fung, Y. K., Trobough, K. L., Cashman, J . R., and
Wilson, J . A. (1991) Depletion of striatal dopamine by N-oxide of
1
-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuro-
toxicology 12, 189-200.
13) Fonne-Pfister, R., Bargetzi, M. J ., and Meyer, U. A. (1987) MPTP,
the neurotoxin inducing parkinson’s disease, is a potent competi-
tive inhibitor of human and rat cytochrome P450 isozymes
(P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.
Biochem. Biophys. Res. Commun. 148, 1144-1150.
14) Fonne-Pfister, R., and Meyer, U. A. (1988) Xenobiotic and
endobiotic inhibitors of cytochrome P-450db1 function, the target
of the debrisoquine/sparteine type polymorphism. Biochem.
Pharmacol. 37, 3829-3835.
(
(
15) Shahi, G. S., Das, N. P., Lee, E. J . D., and Moochhala, S. M. (1988)
1
-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively
depresses brain bufuralol hydroxylase activity in C57 BL/6J mice.
Soc. Neurosci. Abstr. 14, 1217.
(
(
(
(
16) Shahi, G. S., Das, N. P., and Moochhala, S. M. (1990) Parkinson’s
disease and cytochrome P450: A possible link? Med. Hypotheses
3
2, 277-282.
17) Barbeau, A., Cloutier, T., Plasse, L., Roy, M., Paris, S., and Poirier,
J . (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of
debrisoquine. Lancet 2, 1213-1215.
18) Armstrong, M., Daly, A. K., Cholerton, S., Bateman, D. N., and
Idle, J . R. (1992) Mutant debrisoquine hydroxylation genes in
Parkinson’s disease. Lancet 339, 1017-1018.
19) Kurth, M. C., and Kurth, J . H. (1993) Variant cytochrome P450
CYP2D6 allelic frequencies in Parkinson’s disease. Am. J . Med.
Genet. 48, 166-168.
(
32) Suzuki, T., Fujita, S., Narimatsu, S., Masubuchi, Y., Tachibana,
M., Ohta, S., and Hirobe, M. (1992) Cytochrome P450 isozymes
catalyzing 4-hydroxylation of parkinsonism-related compound
1
,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB
J . 6, 771-776.
(
33) Snyder, S. H., and D’Amato, R. J . (1985) Predicting Parkinson’s
disease. Nature 317, 198-199.
TX9500540